Informed Prostate Cancer Patient Support

New Approach For MCRPC | Dr. Catalona Summary The CONTACT-02 study found that a combination treatment of Cabozantinib and Atezolizumab (C+A) can significantly improve outcomes for patients with advanced prostate cancer that has spread to other parts of the body (metastatic castration-resistant prostate cancer or mCRPC) and has progressed after prior hormone therapy. In this phase 3 study, patients receiving the C+A treatment had a longer time before their cancer progressed on scans (radiographic progression-free survival) compared to the control group receiving a second hormone therapy. The improvement was particularly notable in patients with liver metastases and those who had previously received chemotherapy. The C+A group did experience more treatment-related side effects than the control group, with common side effects including hypertension, anemia, diarrhea, and fatigue. However, the side effects were manageable, and a similar percentage of patients in both groups discontinued tr

Real‐world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17‐gene genomic prostate score® (GPSTM) assay - Nguyen - The Prostate - Wiley Online Library Amy M. Nguyen PhD ,  Gebra Cuyun Carter PhD ,  Lesley-Ann Miller Wilson PhD ,  Steven Canfield MD First published: 26 April 2024 https://doi.org/10.1002/pros.24709 Abstract Objectives Descriptive study focusing on real-world utilization and characteristics of men with prostate cancer tested with the 17-gene Genomic Prostate Score® (GPS™) assay by linking administrative claims and electronic health record (EHR) data with GPS results. Methods This retrospective, observational cohort study (January 1, 2013 to D

Dose-escalated Radiotherapy Plus Long-term Androgen Deprivation Therapy Is Safe And Effective For Patients With High-risk Prostate Cancer | Dr. Catalona drcatalona.com © Wade Douglas Carden, MD A study, recently presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco found that high-risk prostate cancer patients benefit from dose-escalation radiotherapy in combination with long-term androgen deprivation therapy (ADT) with no increase in long-term toxicity. The phase-3 trial of patients with high-risk prostate cancer and negative lymph node status was randomly assigned to receive either dose-escalated or conventional dose radiotherapy with ADT given to both groups. The researchers found significantly improved biochemical or clinical progression-free survival in the dose- escalated group versus the conventional-dose group. Also, theresearchers found significant d

  The Genetics Of Prostate Cancer | Dr. Catalona drcatalona.com This SNP data allows one to calculate polygenic risk scores that estimate the combined effects of the many low-risk SNPs that individually increase the risk by a small amount but collectively can increase the risk substantially. Polygenic risk scores are calculated by adding together the number of significantly-associated prostate cancer risk SNPs, multiplying each SNP by its statistical weight. Until very recently the best prostate polygenic risk score included 269 SNPs of the millions of SNPs that have been tested in hundreds of thousands of patients. Although some aggressive cases occur in all of the polygenic risk- score deciles (percentiles grouped into 10 levels are called “deciles”), approximately half of the aggressive cases occur in the top 20th percentile and very few in the bottom tenth. The “latest-and-greatest” prostate cancer po

Prevalence and determinants of shared decision-making for PSA testing in the United States | Prostate Cancer and Prostatic Diseases nature.com Chew, Ben H. Abstract Background Shared decision-making (SDM) is recommended for prostate-specific antigen (PSA) testing but appears underutilized. This population-based study assessed the prevalence and determinants of SDM for PSA testing among US men. Methods We assessed PSA testing rates and SDM engagement in men aged 40 and older without prostate cancer history using the 2019 National Health Interview Survey. SDM was defined as discussing the advantages and disadvantages of PSA testing with a physician. We used multivariable logistic regression with machine learning to identify factors associated with lack of SDM. Results Among 9723 eligible participants (mean age 58 yea

What to Say to Your Partner Who Has Prostate Cancer webmd.com Written by Matt McMillen When you find out that your partner has prostate cancer , both of you probably have a lot of questions about what comes next. There will be plenty you need to talk about. But what do you say -- and what shouldn’t you say -- as you face the disease together? Before you choose your words, focus on the “together” part of this. Your partner will benefit greatly by you being at his side. Go to his appointments with him and be supportive. “If the man has a partner, I always encourage that partner to be there,” says urologist Jesse Mills, MD, director of the Men’s Clinic at UCLA in Los Angeles . “This is a disease that couples suffer together.” Urologist Clayton Lau, MD , agrees. “Say to your partner that you want to be involved, go to appointments, ask questions,” says Lau, dir

Brachytherapy for Prostate Cancer Linked to Higher Risk of Second Pelvic Malignancy | MedPage Today medpagetoday.com Charles Bankhead Oncology/Hematology > Prostate Cancer — Risk for any second malignancy, death from any second malignancy not higher versus prostatectomy by Charles Bankhead , Senior Editor, MedPage Today April 23, 2024 Pelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared with radical prostatectomy, a large retrospective review showed. Second pelvic malignancy -- including bladder and rectum -- rates after brachytherapy

Prognostic impact of prostate‐specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node‐positive prostate cancer - Leow - Journal of Medical Imaging and Radiation Oncology - Wiley Online Library

Article Summary This paper evaluates the performance of different convolutional neural networks (CNNs) in classifying prostate cancer using 3D magnetic resonance imaging (MRI) data. The goal is to develop a model that can reliably predict whether an MRI sequence contains malignant lesions, which could help streamline the diagnosis process and reduce the need for invasive biopsies. The researchers used a dataset provided by Cantonal Hospital Aarau, which included MRI sequences and histopathological reports for each case. They trained three CNN models - ResNet3D, ConvNet3D, and ConvNeXt3D - using various data augmentation techniques, learning rates, and optimizers. The models were evaluated based on their ability to classify the images as either containing malignant lesions or being benign. The best result was achieved by the ResNet3D model, with an average precision score of 0.4583 and an AUC ROC score of 0.6214. However, the models' overall performance was not as high as expected,